A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH

Summary

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .

Timeline

Start

2026-06-30

Primary completion

2029-06-30

Completion

2032-12-30

Drugs

Indications